Atsushi Ohtsu

767 total papers · 42.2k total citations
526 papers, 26.8k citations indexed

About

Atsushi Ohtsu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Atsushi Ohtsu has authored 526 papers receiving a total of 26.8k indexed citations (citations by other indexed papers that have themselves been cited), including 356 papers in Oncology, 334 papers in Pulmonary and Respiratory Medicine and 168 papers in Surgery. Recurrent topics in Atsushi Ohtsu's work include Gastric Cancer Management and Outcomes (262 papers), Colorectal Cancer Treatments and Studies (239 papers) and Esophageal Cancer Research and Treatment (92 papers). Atsushi Ohtsu is often cited by papers focused on Gastric Cancer Management and Outcomes (262 papers), Colorectal Cancer Treatments and Studies (239 papers) and Esophageal Cancer Research and Treatment (92 papers). Atsushi Ohtsu collaborates with scholars based in Japan, United States and South Korea. Atsushi Ohtsu's co-authors include Eric Van Cutsem, Narikazu Boku, Yoon‐Koo Kang, Akira Sawaki, Shigeaki Yoshida, Manabu Muto, Hyun Cheol Chung, Yung‐Jue Bang, Toshihiko Doi and Lin Shen and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Atsushi Ohtsu

516 papers receiving 26.2k citations

Hit Papers

Trastuzumab in combinatio... 2009 2026 2014 2020 2010 2014 2011 2009 2014 1000 2.0k 3.0k 4.0k 5.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation benchmark for papers published in the same subfield and year, or reaches the top citation threshold in at least one of its specific research topics.

  1. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
    2010 5.2k citations Yung‐Jue Bang, Eric Van Cutsem et al. The Lancet profile →
  2. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
    2014 1.7k citations H. Wilke, Kei Muro et al. The Lancet Oncology profile →
  3. Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
    2011 840 citations Atsushi Ohtsu, Manish A. Shah et al. Journal of Clinical Oncology profile →
  4. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study
    2009 470 citations Narikazu Boku, Seiichiro Yamamoto et al. The Lancet Oncology profile →
  5. Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of HER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study
    2014 468 citations Taroh Satoh, Rui‐Hua Xu et al. Journal of Clinical Oncology profile →
  6. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study
    2017 387 citations Peter Thuss‐Patience, Manish A. Shah et al. The Lancet Oncology profile →
  7. Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study
    2013 378 citations Atsushi Ohtsu, Jaffer A. Ajani et al. Journal of Clinical Oncology profile →
  8. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study
    2018 332 citations Josep Tabernero, Paulo M. Hoff et al. The Lancet Oncology profile →
  9. Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial
    2017 292 citations Toshihiro Kudo, Yasuo Hamamoto et al. The Lancet Oncology profile →
  10. Therapeutic landscape and future direction of metastatic colorectal cancer
    2023 90 citations Hideaki Bando, Atsushi Ohtsu et al. Nature Reviews Gastroenterology & Hepatology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Atsushi Ohtsu 17.1k 14.1k 9.8k 4.8k 4.8k 526 26.8k
Florian Lordick 15.9k 0.9× 13.1k 0.9× 10.8k 1.1× 4.1k 0.9× 4.7k 1.0× 518 28.0k
Robert S. Benjamin 14.1k 0.8× 11.8k 0.8× 4.2k 0.4× 3.3k 0.7× 3.9k 0.8× 493 25.8k
Hyun Cheol Chung 14.0k 0.8× 15.1k 1.1× 7.1k 0.7× 4.6k 1.0× 5.6k 1.2× 602 27.7k
Ian Judson 16.4k 1.0× 10.8k 0.8× 5.0k 0.5× 6.4k 1.3× 6.0k 1.3× 402 27.9k
Yoon‐Koo Kang 13.6k 0.8× 12.2k 0.9× 6.9k 0.7× 5.9k 1.2× 5.2k 1.1× 551 26.0k
John Zalcberg 8.0k 0.5× 9.7k 0.7× 5.5k 0.6× 2.9k 0.6× 3.0k 0.6× 410 18.5k
Yung‐Jue Bang 16.9k 1.0× 20.8k 1.5× 7.6k 0.8× 4.5k 0.9× 10.7k 2.3× 609 36.9k
Jaffer A. Ajani 26.7k 1.6× 16.8k 1.2× 21.1k 2.1× 6.6k 1.4× 8.8k 1.8× 937 44.9k
Manish A. Shah 7.9k 0.5× 8.8k 0.6× 5.1k 0.5× 2.1k 0.5× 4.1k 0.9× 334 17.2k
Patrick Schöffski 9.5k 0.6× 9.6k 0.7× 3.2k 0.3× 2.7k 0.6× 4.8k 1.0× 510 19.4k

Countries citing papers authored by Atsushi Ohtsu

Since Specialization
Citations

This map shows the geographic impact of Atsushi Ohtsu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Atsushi Ohtsu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Atsushi Ohtsu more than expected).

Fields of papers citing papers by Atsushi Ohtsu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Atsushi Ohtsu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Atsushi Ohtsu. The network helps show where Atsushi Ohtsu may publish in the future.

Co-authorship network of co-authors of Atsushi Ohtsu

This figure shows the co-authorship network connecting the top 25 collaborators of Atsushi Ohtsu. A scholar is included among the top collaborators of Atsushi Ohtsu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Atsushi Ohtsu. Atsushi Ohtsu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Loading papers...

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xiaoxia Li Breakdown of academic impact, for papers by John F. Stanton Breakdown of academic impact, for papers by Michael Friedländer Breakdown of academic impact, for papers by Marco Valgimigli Breakdown of academic impact, for papers by Marc D. Binder Breakdown of academic impact, for papers by Sterling C. Johnson Breakdown of academic impact, for papers by Paolo Samorı́ Breakdown of academic impact, for papers by Zengqiang Zhang
Rankless by CCL
2026